Mr. Douglas Mason reports

CANADIAN INTERNATIONAL PHARMA CORP. ENTERS INTO LETTER OF INTENT WITH NIKMA DAROU CHIMIE

Canadian International Pharma Corp. has entered into a letter of intent with Nikma Darou Chimie, an Iranian company, setting out the general terms and conditions for a proposed licensing agreement for 99 generic medications. The letter of intent will form the basis of a comprehensive licensing agreement and will be subject to regulatory approval.

The proposed transaction will grant CIPC the rights to manufacture, or have manufactured, market and sell 99 generic medications formulated by Nikma. The list of available medications includes formulations and process for anti-inflammatory and painkillers, cholesterol-lowering agents, anti-anxiety, asthma, antibiotics, cardiovascular medicines, ulcer and reflux, and others, including multiple supplements and vitamins. As part of the proposed transaction, CIPC will issue one million shares to Nikma in exchange for use of the formulations and process for each of the generic medications. Additionally, a licensing royalty is payable by CIPC to Nikma based on sales of medications made based on the formulations.

"This proposed licensing agreement promises to save CIPC valuable time in research and development and enormous expense in introducing medications to international markets. By combining Nikma's more-than-20-years expertise in developing generic formulations and CIPC's ability to market and sell the medications in various markets, we view this as a winning partnership," said Douglas L. Mason, chief executive officer and chairman of Canadian International Pharma.

We seek Safe Harbor.